Analytical Data
-
基因名
Apolipoprotein A-II/APOA2
-
简介
Apolipoprotein A-II/APOA2 protein may stabilize high-density lipoprotein (HDL) structure and affect HDL metabolism through lipid association. As a monomer, APOA2 is critical for maintaining HDL integrity and function. Apolipoprotein A-II/APOA2 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived Apolipoprotein A-II/APOA2 protein, expressed by HEK293 , with C-hFc labeled tag.
- Application
-
别名
Apolipoprotein A-II; Apo-AII; Apolipoprotein A2; ProapoA-II; Apolipoprotein A-II(1-76); APOA2
-
种属
Mouse
-
表达系统
HEK293
-
标签
C-hFc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P09813
-
表达区间
A19-K102
-
蛋白长度
Full Length of Mature Protein
-
分子量
40-45 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Apolipoprotein A-II (APOA2) is a key protein component of high-density lipoproteins (HDL) involved in lipid metabolism and cardiovascular health. Research has indicated its role in modulating HDL structure and function, influencing reverse cholesterol transport, and regulating inflammation. Mutations or variations in the APOA2 gene have been associated with altered lipid profiles and an increased risk of atherosclerosis and coronary artery disease. The interest in recombinant APOA2 protein arises from its potential therapeutic implications, including the development of HDL-mimetic therapies aimed at cardiovascular disease prevention. Furthermore, studies have shown that recombinant APOA2 can enhance lipid efflux capacity and promote cholesterol homeostasis, thereby providing a promising avenue for drug design. The multifaceted roles of APOA2 in lipid regulation and its impact on health make it a significant target for research aimed at understanding lipid disorders and developing effective interventions for heart-related conditions.
